BMT Tandem "Scientific" Meeting
Seaport A-E (Manchester Grand Hyatt)
Chairs:
Krishna V. Komanduri, MD
and
Paul Veys, MBBS
Disclosures:
K. V. Komanduri,
Nothing To Disclose
P. Veys,
Astellas, none:
Honoraria
Gilead, none:
Advisory Board
Pfizer, none:
Honoraria
EUSA, none:
Advisory Board
CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia
Saad S Kenderian, MD, Univeristy of Pennsylvania;
Marco Ruella, MD, Univeristy of Pennsylvania;
Olga Shestova, PhD, Univeristy of Pennsylvania;
Michael Klichinsky, Univeristy of Pennsylvania;
John Scholler, Univeristy of Pennsylvania;
Decheng Song, Univeristy of Pennsylvania;
David L Porter, MD, Univeristy of Pennsylvania;
Martin Carroll, MD, Univeristy of Pennsylvania;
Carl H. June, MD, Univeristy of Pennsylvania;
Saar Gill, MBBS, PhD, Perelman School of Medicine at the University of Pennsylvania
Treatment with Antibiotics Containing Activity Against Obligate Anaerobes Worsens Gvhd Survival in Mice and Humans after Allogeneic BMT
Yusuke Shono, MD, PhD, Memorial Sloan Kettering Cancer Center;
Melissa D. Docampo, Memorial Sloan Kettering Cancer Center;
Odette M. Smith, BA, Memorial Sloan Kettering Cancer Center;
Jyotsna Gupta, Memorial Sloan Kettering Cancer Center;
Sophia R. Liberman, Memorial Sloan Kettering Cancer Center;
Ying Taur, MD, Memorial Sloan Kettering Cancer Center;
Kenya Honda, MD, PhD, Keio University;
Marcel R. M. van den Brink, MD, PhD, Memorial Sloan Kettering Cancer Center;
Robert Jenq, MD, Memorial Sloan Kettering Cancer Center
Graft-Versus-Host Disease Targets Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation
Sonoko Shimoji, MD, Kyushu University Graduate School of Medical Science;
Daigo Hashimoto, MD, PhD, Hokkaido University Graduate School of Medicine;
Koji Kato, MD, PhD, Kyushu University Graduate School of Medical Science;
Hidetsugu Tujigiwa, PhD, Okayama University of Science;
Koichi Akashi, MD, PhD, Kyushu University Graduate School of Medical Science;
Takanori Teshima, MD, PhD, Hokkaido University Graduate School of Medicine
Early Results of a Phase I/ II Study of Gene Therapy for ß -Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral ß AT87Q -Globin Vector
Sandeep Soni, MBBS, MD, bluebird biotech. Inc.;
Alexis A Thompson, MD, Ann and Robert H. Lurie Children’s Hospital;
Mark Walters, MD, Children's Hospital & Research Center, Oakland;
Philippe Leboulch, MD, Brigham and Women's Hospital and Harvard Medical School;
Marina Cavazzana, MD, PhD, Hospital Necker-Enfants Malades
The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma
Craig H. Moskowitz, MD, Memorial Sloan Kettering Cancer Center;
Auayporn Nadamanee, MD, City of Hope National Medical Center;
Tamas Masszi, MD, PhD, Szent Istvan & Szent Laszlo Corporate Hospital Hematology & Stem Cell Dept;
Edward Agura, MD, Baylor Univeristy Medical Center;
Jerzy Holowiecki, MD, PhD, Department of Bone Marrow Transplantation & Oncohematology, Maria Sklodowska-Curie Institute of Oncology;
Muneer H. Abidi, MD, Karmanos Cancer Institute;
Andy Chen, MD, PhD, Oregon Health and Science University;
Patrick J. Stiff, MD, Loyola University Medical Center;
Alessandro M. Gianni, MD, Istituto Nazionale dei Tumori;
Angelo M. Carella, MD, Azienda Ospedaliera Universitaria San Martino-Ist;
Dzhelil Osmanov, MD, Blokhin Cancer Research Center under the Russian Academy of Medical Sciences;
Veronika Bachanova, MD, University of Minnesota Medical Center;
John Sweetenham, MD, Huntsman Cancer Institute, University of Utah;
Anna Sureda, MD, Institut Català d'Oncologia, Hospital Duran i Reynals;
Dirk Huebner, MD, Takeda Pharmaceuticals International Company;
Emily K. Larsen, MS, Seattle Genetics, Inc.;
Naomi N.H. Hunder, MD, Seattle Genetics, Inc.;
Jan Walewski, MD, Maria Sklodowska-Curie Institute and Oncology Center
Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Bone Marrow Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Largest Reported Experience with High Risk Hematologic Malignancies
Heather J. Symons, MD, MHS, The Johns Hopkins University School of Medicine;
Allen Chen, MD, PhD, MHS, Johns Hopkins Hospital;
Christopher Gamper, MD, PhD, Johns Hopkins Hospital;
Kenneth R. Cooke, MD, Johns Hopkins University;
Margaret Showel, MD, MHS, Johns Hopkins University;
Javier Bolaños-Meade, MD, Johns Hopkins University;
Leo Luznik, MD, The Johns Hopkins University School of Medicine;
Richard J. Jones, MD, The Johns Hopkins University;
Ephraim J. Fuchs, MD, MBA, Johns Hopkins University School of Medicine
![[Visit Client Website]](images/banner.gif)